Stockreport

MAIA Biotechnology Awarded $2.3 Million Grant by National Institutes of Health for THIO-101 Phase 2 Trial of Cancer-Fighting Agent [Yahoo! Finance]

MAIA Biotechnology, Inc.  (MAIA) 
PDF CHICAGO, Sept. 24, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused o [Read more]